knowledge -WSS

knowledge

author：focus 2025-09-29 17:01:55 - browse：4548

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

The release of Novo Nordisk’s latest earnings report on Thursday provided a chance for executives to tout their major win this week — outcomes from a large trial showing the company’s obesity drug Wegovy cut the risk of heart complications by 20%.

But once again, much of the attention was focused on the company’s struggles to meet what Novo CEO Lars Fruergaard Jørgensen referred to as the “overwhelming demand for Wegovy.”

Jørgensen reiterated that the company was racing to expand supply and had brought on more contract manufacturing support, but Novo said Thursday that the company would continue to restrict the availability of lower-strength starter doses in the United States to ensure that patients on the drug would not have their medication interrupted.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： The (many) problems with a new study criticizing cancer screening

WSS

Winners, losers from Medicare’s list of drugs subject to price talks

Seth Rogen and Lauren Miller Rogen on Alzheimer's caregiving

Amazon on where the company's health care bets are headed next

NYU Langone launches private ChatGPT for its health care data

CDC advisory panel says seniors 'may' get RSV vaccine

Drug firms test therapies to halt Alzheimer’s before symptoms arise

Wikipedia

knowledge

hotspot

Dobbs anniversary: the lost opportunity of abortion as health care

Diversity in medical illustrations gets boost from Chidiebere Ibe

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

AstraZeneca challenges Medicare drug negotiation program

Malaria cases in Florida and Texas: Here’s what you need to know

How to make AI work for medicine

Affirmative action in medical school literally saved lives

ALS advocates say criticism of new drugs misses bigger picture

How to save PrEP access — and even expand it

Neuroscience startup Neumora files for IPO

entertainment

How Long Island became the ‘eugenics capital of the world’

NIH nominee Bertagnolli will get October confirmation hearing

A rare thyroid diagnosis led to unexpected, all

ALS advocates say criticism of new drugs misses bigger picture

AstraZeneca challenges Medicare drug negotiation program

The 10 drugs up first for Medicare price negotiation

focus

focus

explore

Wikipedia